Vaccine Efficacy of Fusogenic Liposomes Containing Tumor Cell-Lysate against Murine B16BL6 Melanoma

DOI Web Site Web Site PubMed 7 Citations 36 References
  • Yoshikawa Tomoaki
    Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Osaka University “Creation of bio-devices and bio-systems with chemical and biological molecules for medical use”, CREST, Japan Science and Technology Agency (JST)
  • Okada Naoki
    Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Osaka University Department of Biopharmaceutics, Kyoto Pharmaceutical University
  • Tsujino Masaki
    Department of Biopharmaceutics, Kyoto Pharmaceutical University
  • Gao Jian-Qing
    Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Osaka University Department of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University
  • Hayashi Akira
    Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Osaka University
  • Tsutsumi Yasuo
    National Institute of Biomedical Innovation, Japan
  • Mayumi Tadanori
    Kobegakuin University
  • Yamamoto Akira
    Department of Biopharmaceutics, Kyoto Pharmaceutical University
  • Nakagawa Shinsaku
    Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Osaka University “Creation of bio-devices and bio-systems with chemical and biological molecules for medical use”, CREST, Japan Science and Technology Agency (JST)

Search this article

Abstract

Recent advances in tumor immunology have facilitated the development of cancer immunotherapy targeting tumor-associated antigens (TAAs). However, because TAAs were identified in only a few types of human cancer, novel vaccine strategies that utilize tumor cell-lysate (TCL), including unidentified TAAs as an antigen source, are needed. Herein, we describe the utility of fusogenic liposomes (FLs) as TCL-delivery carriers for both ex vivo dendritic cell-based vaccination and in vivo direct immunization in the murine B16BL6 melanoma model. As a result, both in vivo direct immunization and ex vivo immunization induced anti-B16 melanoma prophylactic effects. Ex vivo dendritic cell (DC)-mediated vaccination strategy exert more potent anti-tumor effect than direct immunization. Our results suggest that this flexible system is a promising approach for the development of versatile cancer immunotherapy regimes.

Journal

Citations (7)*help

See more

References(36)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top